NASDAQ$CYRX
CryoPort Inc. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2023.
Cryoport reported full year revenue of $233.3 million. The services business increased to 62% of total revenue, with year-over-year growth in BioStorage/BioServices and support of commercial Cell & Gene therapies of 45% and 33%, respectively. The company supported a record 675 clinical trials worldwide.
- Total revenue for FY 2023 was $233.3 million.
- Services business increased to 62% of total revenue.
- Revenues from BioStorage/BioServices grew 45% year-over-year.
- Supported 675 global clinical trials, a net increase of 21 clinical trials over the prior year.
Headline financials
Revenue & EPS history
CryoPort · Revenue · Quarterly
$57.3M
Forward guidance
The Company is expecting revenue to grow progressively and is providing full year 2024 revenue guidance of $242 - $252 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
28 / 57 earnings
Positive
+31.6%
Q4 2013
Best reaction
-33.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.4% | +33.2% | +58.2% | |
| Q4 2025 | +2.9% | -4.7% | +3.3% | |
| Q3 2025 | -8.2% | -7.4% | +3.5% | |
| Q1 2025 | +23.4% | +23.3% | +23.7% | |
| Q4 2024 | +30.6% | -7.1% | +5.7% | |
| Q3 2024 | -3.6% | -0.9% | -8.6% | |
| Q2 2024 | +3.9% | +10.0% | +9.8% | |
| Q1 2024 | -17.5% | -16.7% | -30.6% | |
| Q4 2023 | -12.3% | -7.3% | +10.3% | |
| Q3 2023 | +8.9% | +8.4% | +46.7% | |
| Q2 2023 | -0.2% | +1.2% | -5.0% | |
| Q1 2023 | +13.9% | +4.5% | -6.3% | |
| Q4 2022 | +13.7% | +9.9% | +15.3% | |
| Q3 2022 | -33.8% | -35.7% | -26.5% | |
| Q2 2022 | +6.8% | +5.2% | -16.1% | |
| Q1 2022 | -8.5% | -14.6% | -2.8% | |
| Q4 2021 | +9.3% | +7.0% | +1.9% | |
| Q3 2021 | -1.0% | -1.2% | -22.8% | |
| Q2 2021 | -1.5% | -3.6% | +2.9% | |
| Q1 2021 | +9.0% | +11.6% | -2.4% | |
| Q4 2020 | -0.7% | -11.7% | -12.5% | |
| Q3 2020 | +5.0% | +24.2% | +12.8% | |
| Q2 2020 | -2.0% | -5.0% | +55.5% | |
| Q1 2020 | +2.0% | +17.0% | +22.6% | |
| Q4 2019 | +2.1% | +0.8% | -11.9% | |
| Q3 2019 | +1.4% | +3.9% | +5.6% | |
| Q2 2019 | +19.7% | +24.5% | +2.3% | |
| Q1 2019 | +12.5% | +12.5% | +17.7% | |
| Q4 2018 | -0.6% | +6.6% | +22.3% | |
| Q3 2018 | -1.0% | -9.4% | -2.0% | |
| Q2 2018 | -1.6% | -14.7% | -6.5% | |
| Q1 2018 | +11.8% | +23.0% | +67.4% | |
| Q4 2017 | +3.8% | +6.4% | -7.0% | |
| Q3 2017 | -15.1% | -22.9% | -10.5% | |
| Q2 2017 | -2.0% | +3.6% | +28.6% | |
| Q1 2017 | +8.2% | +9.0% | +46.9% | |
| Q4 2016 | +23.7% | +9.0% | +23.7% | |
| Q2 2016 | -7.5% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | -3.0% | — | — | |
| Q3 2015 | +7.5% | — | — | |
| Q2 2015 | -14.4% | — | — | |
| Q1 2015 | -2.2% | — | — | |
| Q4 2014 | +6.4% | — | — | |
| Q3 2014 | -5.6% | — | — | |
| Q4 2013 | +31.6% | — | — | |
| Q3 2013 | -8.0% | — | — | |
| Q2 2013 | +5.3% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -3.1% | — | — | |
| Q3 2012 | -10.8% | — | — | |
| Q2 2012 | -8.0% | — | — | |
| Q1 2012 | -2.7% | — | — | |
| Q1 2010 | +11.2% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q2 2009 | -2.8% | — | — | |
| Q1 2009 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro